Hendriks LEL, et al. - Survival of patients with non-small cell lung cancer (NSCLC) having leptomeningeal metastases (LM) treated with immune checkpoint inhibitors (ICIs) was investigated. From 7 European centres, researchers merged patients with advanced NSCLC treated with ICIs between November 2012 and July 2018 and selected all patients with LM before ICI start. They identified LM in 19 of 1288 (1.5%) patients; 73.7% had synchronous brain metastases; 73.7% had neurological symptoms at the start of ICIs and 52.6% were in the National Comprehensive Cancer Network (NCCN) LM good prognosis group. They observed the 6-month overall survival (OS) rate of 36.8%, and the 12-month OS rate of 21.1%; the good vs poor NCCN prognostic group was not statistically significantly different regarding the two. Findings suggest that ICI treatment does benefit some patients with NSCLC having LM; specifically, those in the NCCN LM good prognosis group can obtain a long survival.